Revolution Medicines’ (RVMD) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Revolution Medicines (NASDAQ:RVMD) in a report published on Wednesday,Benzinga reports.

Other equities analysts have also recently issued reports about the stock. Benchmark reissued an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. UBS Group assumed coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They issued a “buy” rating for the company. Stifel Nicolaus reissued a “buy” rating on shares of Revolution Medicines in a research report on Monday. Truist Financial raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Evercore reissued an “outperform” rating on shares of Revolution Medicines in a research report on Tuesday, April 14th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $78.94.

Revolution Medicines Stock Down 5.0%

Shares of NASDAQ RVMD opened at $141.50 on Wednesday. Revolution Medicines has a 12-month low of $34.00 and a 12-month high of $155.70. The company has a market cap of $28.04 billion, a P/E ratio of -23.94 and a beta of 1.01. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The stock has a fifty day moving average price of $106.04 and a 200 day moving average price of $88.28.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the previous year, the business posted ($1.12) earnings per share. Research analysts anticipate that Revolution Medicines will post -7.57 EPS for the current fiscal year.

Insider Buying and Selling at Revolution Medicines

In other news, insider Lin Wei sold 2,073 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $206,222.04. Following the transaction, the insider owned 101,366 shares of the company’s stock, valued at approximately $10,083,889.68. This trade represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Margaret A. Horn sold 4,583 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the sale, the chief operating officer owned 157,570 shares in the company, valued at approximately $15,675,063.60. This trade represents a 2.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 184,592 shares of company stock valued at $24,499,532. Corporate insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Revolution Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the business. Janney Montgomery Scott LLC acquired a new stake in Revolution Medicines during the first quarter worth about $240,000. Citrine Capital LLC acquired a new stake in Revolution Medicines during the first quarter worth about $243,000. Cannon Global Investment Management LLC acquired a new stake in Revolution Medicines during the first quarter worth about $827,000. Aaron Wealth Advisors LLC acquired a new stake in Revolution Medicines during the first quarter worth about $236,000. Finally, Ritholtz Wealth Management acquired a new stake in Revolution Medicines during the first quarter worth about $362,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Phase 3 RASolute 302 reported an unprecedented overall survival benefit for daraxonrasib and the full trial results will be presented in a Plenary Session at ASCO (May 31). This is a major clinical and commercial inflection point if the detailed data and safety profile hold up. Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results
• Positive Sentiment: Updated Phase 1/2 daraxonrasib data in first-line metastatic pancreatic cancer will be presented at AACR (late-breaking mini-symposium and poster), reinforcing momentum across both later- and earlier-line programs. Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib
• Positive Sentiment: Preclinical data on RM-055 (a mutant-targeted catalytic RAS(ON) inhibitor) show activity across resistant models and multiple tumor types — adds depth to the pipeline beyond daraxonrasib. Revolution Medicines to Present Preclinical Data on RM-055
• Positive Sentiment: Multiple brokerages (HC Wainwright, Stifel and others) have reiterated or maintained Buy/Outperform ratings and elevated price targets recently, supporting continued analyst optimism around commercialization potential. HC Wainwright Buy Rating Reaffirmed (Benzinga)
• Neutral Sentiment: Several Revolution-sponsored abstracts (real‑world analyses, safety/efficacy in later lines) were accepted for publication — useful for market narrative but less likely to move the stock than pivotal OS/PFS readouts. Additional Accepted Abstracts (GlobeNewswire)
• Negative Sentiment: Notable insider selling and large institutional position reductions have been reported in recent quarters — heavy insider sales and major funds trimming can exert selling pressure and reduce investor confidence. Quiver / Insider & Institutional Activity
• Negative Sentiment: Daraxonrasib remains investigational and regulatory approval, full safety readouts, and commercialization execution are still future events — these risks (plus the company’s prior EPS misses and cash burn profile) keep the story binary and can drive volatile trading. Regulatory & Forward-Looking Risks

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.